Ascertainment strategies and genotype:phenotype correlations in hypertrophic cardiomyopathy.

Ascertainment strategies and genotype:phenotype correlations in hypertrophic cardiomyopathy.

Detalhes bibliográficos
Main Authors:	Blair, E, Redwood, C, Watkins, H
Formato:	Journal article
Idioma:	English
Publicado em:	2003

Registos relacionados

Mutations in cis can confound genotype-phenotype correlations in hypertrophic cardiomyopathy.
Por: Blair, E, et al.
Publicado em: (2001)

Double mutations in CIS can confound genotype-phenotype correlations in hypertrophic cardiomyopathy
Por: Blair, E, et al.
Publicado em: (2000)

Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.
Por: Ashrafian, H, et al.
Publicado em: (2003)

A Genotype-phenotype Taxonomy of Hypertrophic Cardiomyopathy
Por: Lara Curran, BSc, et al.
Publicado em: (2024-01-01)

Functional analysis of hypertrophic cardiomyopathy missense mutations in the light meromyosin region of beta myosin heavy chain
Por: Redwood, C, et al.
Publicado em: (2003)

Pediatric Hypertrophic Cardiomyopathy: Exploring the Genotype‐Phenotype Association
Por: Minh B. Nguyen, et al.
Publicado em: (2022-03-01)

A novel mutation in phospholamban causes a mixed hypertrophic and dilated cardiomyopathy phenotype with autosomal dominant inheritance
Por: Carballo, S, et al.
Publicado em: (2004)

Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy.
Por: Elliott, K, et al.
Publicado em: (2000)

Linked genetic modifiers in hypertrophic cardiomyopathy
Por: Ektisham, J, et al.
Publicado em: (2004)

Investigation of troponin I mutations causing familial hypertrophic cardiomyopathy
Por: Abdulrazzak, H, et al.
Publicado em: (2001)

Effects of hypertrophic cardiomyopathy mutations in troponin I on contractility of skinned cardiac muscle fibres
Por: Burton, D, et al.
Publicado em: (2002)

Early onset malignant hypertrophic cardiomyopathy caused by mutations in MYBPC3
Por: Carballo, S, et al.
Publicado em: (2003)

Sudden death in hypertrophic cardiomyopathy.
Por: Watkins, H
Publicado em: (2000)

Altered inhibitory and troponin C-binding activities in cardiac troponin I mutants known to cause hypertrophic cardiomyopathy
Por: Elliott, K, et al.
Publicado em: (2000)

Correlates of myocardial fibrosis in hypertrophic cardiomyopathy
Por: Kramer, CM, et al.
Publicado em: (2018)

Myocardial dysfunction in hypertrophic cardiomyopathy.
Por: Ashrafian, H, et al.
Publicado em: (2001)

Novel mutations in cardiac MYBPC3 and early onset malignant hypertrophic cardiomyopathy
Por: Carballo, S, et al.
Publicado em: (2005)

Delineating the role of adenosine monophosphate (AMP)-activated protein kinase (AMP) gamma 2 subunit in hypertrophic cardiomyopathy (HCM)
Por: Grignani, R, et al.
Publicado em: (2005)

Mutations of the light meromyosin domain of the beta-myosin heavy chain rod in hypertrophic cardiomyopathy.
Por: Blair, E, et al.
Publicado em: (2002)

Hypertrophic cardiomyopathy mutations in the gamma 2 subunit of AMP-activated kinase suggest a central role of energy compromise in disease pathogenesis
Por: Blair, E, et al.
Publicado em: (2001)

Comparison of the functional effects of mutations in troponin T which cause dilated and hypertrophic cardiomyopathies
Por: Robinson, P, et al.
Publicado em: (2002)

Is DNA testing for hypertrophic cardiomyopathy cost-effective?
Por: Wordsworth, S, et al.
Publicado em: (2006)

Novel mutations in cardiac MYBPC3 causing early onset malignant hypertrophic cardiomyopathy
Por: Carballo, S, et al.
Publicado em: (2005)

Restrictive cardiomyopathy and hypertrophic cardiomyopathy overlap: the importance of the phenotype
Por: Juan Pablo Kaski, et al.
Publicado em: (2012-10-01)

Metabolic perturbations in the pathogenesis of hypertrophic cardiomyopathy
Por: Ashrafian, H, et al.
Publicado em: (2005)

Novel mutations in cardiac MYPBC3 cause early onset malignant hypertrophic cardiomyopathy (HCM)
Por: Carballo, S, et al.
Publicado em: (2005)

Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging.
Por: Robert J H Miller, et al.
Publicado em: (2019-01-01)

Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments.
Por: Robinson, P, et al.
Publicado em: (2007)

Spectrum and genotype–phenotype relationship of ALPK3 variants in Chinese patients with hypertrophic cardiomyopathy
Por: Jing Wang, et al.
Publicado em: (2024-06-01)

Late gadolinium enhancement cardiovascular magnetic resonance in genotyped hypertrophic cardiomyopathy with normal phenotype
Por: Jassal Davinder S, et al.
Publicado em: (2008-12-01)

The genetics of hypertrophic cardiomyopathy: Teare redux.
Por: Watkins, H, et al.
Publicado em: (2008)

Hypertrophic cardiomyopathy in Noonan Syndrome closely mimics familial hypertrophic cardiomyopathy due to sarcomeric mutations.
Por: Hudsmith, L, et al.
Publicado em: (2006)

Genetic determinants of clinical phenotype in hypertrophic cardiomyopathy
Por: Lazar Velicki, et al.
Publicado em: (2020-12-01)

Hypertrophic Cardiomyopathy: From Phenotype and Pathogenesis to Treatment
Por: Zeyi Cheng, et al.
Publicado em: (2021-10-01)

A troponin I mutant known to cause hypertrophic cardiomyopathy shows reduced inhibition of Ca2+ independent tension
Por: Burton, D, et al.
Publicado em: (2000)

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.
Por: Wordsworth, S, et al.
Publicado em: (2010)

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model
Por: Wordsworth, S, et al.
Publicado em: (2010)

Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies.
Por: Watkins, H
Publicado em: (2003)

[Abnormal tropomyosin function in ATPase cycle in hypertrophic and dilated cardiomyopathies].
Por: Borovikov, I, et al.
Publicado em: (2013)

Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin
Por: Toepfer, C, et al.
Publicado em: (2019)